Browsing by Author "Kahraman, S."

Now showing 1 - 2 of 2

Oxidative Stress Markers in Ivf Patients and Their Association With Pregnancy Results
(Turkiye Klinikleri, 2014) Güler Okyay, A.; Aslan, M.; Taşkin, A.; Selek, S.; Ceng Altin, G.; Kahraman, S.
Objective: Oxidative stress has been well recognized as a component in the pathogenesis of many diseases, including female infertility. In this study, we aimed to investigate serum paraoxonase (PON1), arylesterase and myeloperoxidase (MPO) activities, and lipid hydroperoxide (LOOH) levels as oxidative stress markers along with their relationship with the pregnancy rate in women undergoing in vitro fertilization (IVF) treatment. Material and Methods: Serum samples of 179 subjects were collected immediately before starting ovarian stimulation and on ovum pick-up (OPU) day during IVF treatment. Stimulation protocol and starting doses were determined individually. When the leading follicle reached at least 17 mm in size, recombinant human chorionic gonadotropin (Ovitrelle, 250 mcg, Serono) was administered for ovulation induction. Serum basal/salt-stimulated paraoxonase, arylesterase activities, myeloperoxidase activity, and lipid hydroperoxide levels were compared between two samples. Subjects were also divided into two groups according to the presence of pregnancy, and the groups were compared in terms of oxidative stress markers studied. Results: Serum MPO activity and LOOH levels were significantly higher on ovum pick up day (p<0.05, p<0.001, respectively), while basal/salt-stimulated paraoxonase and arylesterase activities were significantly lower (p=0.012, p=0.041, respectively) than those before ovarian stimulation. Serum LOOH levels on OPU day were significantly higher in non-pregnant group than pregnant one (p<0.001). Although basal/salt-stimulated paraoxonase, arylesterase and myeloperoxidase activities were higher in the non-pregnant group compared to the pregnant group, it was not statistically significant (p>0.05). Conclusion: Ovarian stimulation during IVF treatment resulted in increased oxidative stress and decreased PON1 activity. However, changes in the studied parameters were not found to be significantly associated with the pregnancy results. Further studies are required to clarify our results. © 2014 by Türkiye Klinikleri.
Real-World Treatment Efficacy of Ribociclib or Palbociclib Plus Fulvestrant in Hormone Receptor-positive/Her2-negative Metastatic Breast Cancer: Turkish Oncology Group (Tog) Study
(Elsevier Inc., 2025) Kahraman, S.; Erul, E.; Gumusay, O.; Guven, D.C.; Aksoy, S.; Basaran, G.; Sendur, M.A.N.
Background: Real-world (RW) data provide valuable information about the effectiveness and safety of treatment modalities in the general population that is not limited by selection criteria in clinical studies. The aim of this study was to evaluate the effectiveness of palbociclib or ribociclib plus fulvestrant in hormone receptor-positive and human epidermal factor 2-negative metastatic breast cancer (HR+/HER2-MBC). Materials and methods: We conducted a multicenter, retrospective cohort study that included 522 patients with HR+/HER2-MBC treated with ribociclib or palbociclib in combination with fulvestrant. Results: Median real-world progression-free survival (mPFS) was 12.9 months (95% CI, 11.16-14.65) for the entire cohort, and no statistically significant difference was present between the palbociclib and ribociclib groups (P = .70). Real-world median overall survival (mOS) was estimated to be 43.3 months (95% CI, 20-66.6) for the palbociclib group and 48.5 months (95% CI, NA-NA) for the ribociclib group and similar between the 2 groups (P = .56). When evaluated for the entire group, there was a significant difference in mPFS between patients with primary and secondary endocrine resistance (8.6 and 13.5 months, P = .002), and this difference was more pronounced in the palbociclib arm (6.6 and 14.4 months, P = .006) than in the ribociclib arm (11.6 and 13.3 months, P = .064). Conclusion: Although the 3 CDK4/6 inhibitors did not seem to differ significantly from each other in terms of effectiveness in a real-world context, they may vary depending primarily on the specific characteristics of the patient population being treated. © 2025 Elsevier Inc.